Loading…
MBX Biosciences, Inc. is projected to rise to $99.10 by 2027, a +62% move from its current price of $61.05. MBX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $58.57 | $61.09 | $63.71 | +0.06% |
| Jul 14 | $57.59 | $61.12 | $64.86 | +0.12% |
| Jul 15 | $56.86 | $61.16 | $65.77 | +0.17% |
| Jul 16 | $56.26 | $61.19 | $66.56 | +0.23% |
| Jul 17 | $55.74 | $61.23 | $67.26 | +0.29% |
| Jul 18 | $55.27 | $61.26 | $67.90 | +0.35% |
| Jul 19 | $54.85 | $61.30 | $68.51 | +0.41% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $54.85 | $61.30 | $68.51 | +0.41% |
| Week 2 | $52.60 | $61.55 | $72.03 | +0.82% |
| Week 3 | $50.98 | $61.80 | $74.92 | +1.23% |
| Week 4 | $49.68 | $62.05 | $77.50 | +1.64% |
| Week 5 | $48.59 | $62.31 | $79.89 | +2.06% |
| Week 6 | $47.65 | $62.56 | $82.14 | +2.47% |
| Week 7 | $46.81 | $62.82 | $84.30 | +2.89% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focusing on the discovery and development of precision peptide therapies for endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
In addition, it is developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX Biosciences also has MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. is a clinical-stage healthcare company trading at $62.00 with a market capitalization of $2.95B and a market rank of 1760.
A major floor 75.1% below — a decisive break under it would weaken the trend.
The nearest floor, 52.5% below — buyers have tended to step in here.
The nearest ceiling, 7.6% above — a clean break opens room to run.
A major ceiling 45.2% above — clearing it would confirm fresh momentum.
Key MBX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MBX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $61.64 | Sell | $61.24 | Sell |
| MA 10 | $58.33 | Buy | $57.96 | Buy |
| MA 20 | $50.44 | Buy | $51.96 | Buy |
| MA 50 | $39.45 | Buy | $43.19 | Buy |
| MA 100 | $35.58 | Buy | $37.92 | Buy |
| MA 200 | $31.62 | Buy | $32.34 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 74.18 | Sell |
| Stoch RSI (14) | 3.01 | Buy |
| CCI (20) | 89.67 | Neutral |
| Williams %R (14) | -21.38 | Info |
| MACD (12,26,9) | 1.04 | Buy |
| ROC (12) | 31.60 | Buy |
| Bollinger %B (20,2) | 0.80 | Neutral |
| Stochastic %K (14) | 78.62 | Neutral |
| TRIX (15) | 2.33 | Buy |
| Awesome (5,34) | 19.23 | Buy |
| Ultimate (7,14,28) | 73.93 | Sell |
| Momentum (10) | 10.68 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 64.80 | Sell |
| ADX (14) | 50.55 | Buy |
| ATR (14) | 1.93 | Info |
The near-term technical picture is bullish, with RSI14 at 90 indicating strong momentum. The stock trades on a backdrop where the SMA50 is $37.54 and the SMA200 is $30.88, showing upside potential as price moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $26.92 | $61.05 | $91.00 | 0% | Neutral | |
| $74.95 | $99.10 | $140.70 | +62% | Bullish | |
| $73.08 | $101.13 | $151.38 | +66% | Bullish | |
| $81.38 | $117.03 | $182.47 | +92% | Bullish | |
| $90.43 | $134.60 | $217.10 | +120% | Bullish | |
| $87.12 | $133.85 | $222.32 | +119% | Bullish | |
| $114.25 | $180.88 | $308.37 | +196% | Bullish | |
| $140.87 | $229.48 | $400.53 | +276% | Bullish | |
| $151.42 | $253.52 | $452.10 | +315% | Bullish | |
| $172.15 | $295.97 | $538.38 | +385% | Bullish | |
| $252.22 | $491.11 | $969.79 | +704% | Bullish | |
| $385.29 | $856.19 | $1,900.19 | +13.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $26.92 | $61.05 | $72.27 | +0.00% |
| August 2026 | $51.02 | $61.10 | $75.75 | +0.08% |
| September 2026 | $53.17 | $64.38 | $81.16 | +5.37% |
| October 2026 | $52.65 | $64.35 | $82.27 | -0.04% |
| November 2026 | $52.51 | $64.70 | $83.68 | +0.54% |
| December 2026 | $56.07 | $69.61 | $91.00 | +7.59% |
Click any year to see its month-by-month MBX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The MBX price prediction for 2026 points to an average of $61.05 (low $26.92, high $91.00) — a potential gain of 0% on today's $61.05. Price action looks broadly range-bound.
In 2027, MBX is projected to trade between $74.95 and $140.70, averaging $99.10 — a potential gain of +62% from today's $61.05. That is up +62% on the projected 2026 average. Buyers look set to stay in control over this stretch.
MBX Biosciences, Inc.'s 2028 outlook centres on $101.13, within a $73.08 to $151.38 range. That is up +2% on the projected 2027 average. That marks a +66% change versus current levels. Momentum favours further upside here.
By 2029, MBX could reach as high as $182.47, with a base case around $117.03 and support toward $81.38 — roughly +92% from $61.05. Buyers look set to stay in control over this stretch.
Expect MBX to range from $90.43 to $217.10 through 2030. The $134.60 average target implies a +120% move from current prices. That is up +15% on the projected 2029 average. Momentum favours further upside here.
The MBX price prediction for 2031 points to an average of $133.85 (low $87.12, high $222.32) — a potential gain of +119% on today's $61.05. Buyers look set to stay in control over this stretch.
In 2032, MBX is projected to trade between $114.25 and $308.37, averaging $180.88 — a potential gain of +196% from today's $61.05. That is up +35% on the projected 2031 average. Momentum favours further upside here.
MBX Biosciences, Inc.'s 2033 outlook centres on $229.48, within a $140.87 to $400.53 range. That is up +27% on the projected 2032 average. That marks a +276% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, MBX could reach as high as $452.10, with a base case around $253.52 and support toward $151.42 — roughly +315% from $61.05. Momentum favours further upside here.
Expect MBX to range from $172.15 to $538.38 through 2035. The $295.97 average target implies a +385% move from current prices. That is up +17% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The MBX price prediction for 2040 points to an average of $491.11 (low $252.22, high $969.79) — a potential gain of +704% on today's $61.05. Momentum favours further upside here.
In 2050, MBX is projected to trade between $385.29 and $1,900.19, averaging $856.19 — a potential gain of +13.0x from today's $61.05. That is up +74% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in MBX today (≈ 16.380016 MBX) could be worth
$14,024.4
+$13,024.4 (+1302%) by 2050 · US Dollar
Based on the average projected MBX price of $856.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MBXwould be worth at today's price.
$1,000 invested in MBX on Jul 10, 2025 (≈ 80.645164 MBX) would be worth
$4,923.39
+$3,923.39 (+392.3%) today · 4.92× · US Dollar
Based on a MBX entry price of $12.4 vs. today's $61.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $57.8 | $1,056.23 | +5.6% |
| 1 month ago | $30.99 | $1,969.99 | +97.0% |
| 3 months ago | $31 | $1,969.35 | +96.9% |
| 6 months ago | $36.47 | $1,673.98 | +67.4% |
| 1 year ago | $12.4 | $4,923.39 | +392.3% |
| All time (1.8y) ago | $23.65 | $2,581.4 | +158.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MBX forecast.
Our base-case forecast reaches $120.00 around 2030.
Implied market cap at $120.00: $5.71B
Forecasts show a clear long-run uptrend with a rising average price and substantial upside. For 2030, the avg is $135.55 with a max of $217.01 and a min of $91.78, yielding an ROI of 118.6% and a bullish sentiment. By 2040, the avg climbs to $483.34 with a max of $943.75 and a min of $252.91, delivering a 679.6% ROI in that horizon.
In 2050, the avg is $849.14 with a max of $1,859.97 and a min of $382.11, for a 1269.6% ROI and continued bullish sentiment. These figures illustrate strong multi-year upside but remain estimates, not guarantees, and are subject to market and clinical developments and other risks.
Tap a question to reveal the answer.
Forecast for 2030 shows an average price of $135.55, a min of $91.78, a max of $217.01, and an ROI of 118.6%, with a bullish sentiment.
Forecasts indicate bullish sentiment across 2027–2050, with rising averages (e.g., $99.80 in 2027, $102.53 in 2028, $119.02 in 2029, $135.55 in 2030) and ROI climbing to 118.6% by 2030 and 1269.6% by 2050.
Yes. The 2030 max forecast is $217.01, which exceeds $200.
Current price is $62.00 and market capitalization is $2.95B.
RSI14 is 90; 30-day range is $47.36 to $81.16; support is $29.00; resistance is $62.00; SMA50 is $37.54; SMA200 is $30.88; sentiment is bullish and annualized volatility is 80%.
MBX Biosciences, Inc. Community Discussion
0Share your MBX Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.